Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

yf_tkr_AZN · 2026-10-24 · Bullish AI sentiment

$AZN

WILMINGTON, Del., October 24, 2026--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible

Sector coverage: Healthcare · Drug Manufacturers - General

Read the original at yf_tkr_AZN ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.